Report from Tribunnews.com Journalist, Rina Ayu
TRIBUNNEWS.COM, JAKARTA – Dendritic Cell Vaccine or what is known as the Nusantara vaccine is again reaping controversy.
Several members of the DPR RI want to volunteer for clinical trials even though BPOM RI found irregularities in the research and development of Indonesian vaccines.
Head of the Eijkman Institute for Molecular Biology (LBM), Prof. Amin Subandrio, was of the view that the Nusantara vaccine cannot be developed en masse.
This refers to the basis of the vaccine, namely dentritic cells.
Also read: Chairperson of BEM UI Asks to Stop Politicization of Archipelago Vaccines
The cells taken from the person’s body are then processed, loaded with antigens.
“And injected again with the same person. So it must be injected into the same person,” he said in a virtual public lecture entitled ‘Regarding Covid-19 Vaccination; Recognize Types and Side Effects’, Wednesday (14/4/2021).
Also read: Researchers Explain the Stages of Archipelago Vaccine Research
He said that if these cells were injected into another person, it would likely cause a graft versus host disease reaction or a condition when donor bone marrow or stem cells attack the recipient.
“Because each person’s cell has its own category, when it is inserted into another person’s body, there is rejection,” he explained.
Also read: Nusantara Vaccine Polemic, Dasco: Don’t Fight DPR against BPOM
“It can generate an immune response but cannot be used in bulk individually,” added Amin.
–
